| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11010-007-9485-7 |
| P698 | PubMed publication ID | 17549607 |
| P2093 | author name string | Takao Satou | |
| Masanobu Tsubaki | |||
| Shozo Nishida | |||
| Tatsuki Itoh | |||
| Hiroshi Matsuoka | |||
| Chisato Kato | |||
| Mitsuhiko Ogaki | |||
| Takashi Kusunoki | |||
| Yoshihiro Tanimori | |||
| Kimiko Fujiwara | |||
| Miyuki Manno | |||
| P2860 | cites work | Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL | Q24682139 |
| Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand | Q30670375 | ||
| A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function | Q33542094 | ||
| Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression | Q33944735 | ||
| Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2. | Q40465940 | ||
| Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein | Q40699804 | ||
| Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts | Q40838654 | ||
| Expression levels of gp130 in bone marrow stromal cells determine the magnitude of osteoclastogenic signals generated by IL-6-type cytokines | Q40853809 | ||
| STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroi | Q40945774 | ||
| Establishment and characterization of an immortal macrophage-like cell line inducible to differentiate to osteoclasts. | Q41065416 | ||
| p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function | Q44072080 | ||
| Stimulation of osteoclast formation by 1,25-dihydroxyvitamin D requires its binding to vitamin D receptor (VDR) in osteoblastic cells: studies using VDR knockout mice. | Q54106653 | ||
| Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS) | Q57904962 | ||
| Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand | Q73211247 | ||
| p44/42 MAPK activation is necessary for receptor activator of nuclear factor-kappaB ligand induction by high extracellular calcium | Q73343165 | ||
| Knockout of the murine prostaglandin EP2 receptor impairs osteoclastogenesis in vitro | Q73832169 | ||
| Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma | Q74676116 | ||
| Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment | Q77337113 | ||
| Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma | Q77337118 | ||
| MIP-1 gamma promotes receptor-activator-of-NF-kappa-B-ligand-induced osteoclast formation and survival | Q80363114 | ||
| Annexin II stimulates RANKL expression through MAPK | Q81820774 | ||
| P433 | issue | 1-2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | osteoblast | Q917177 |
| P304 | page(s) | 53-60 | |
| P577 | publication date | 2007-06-05 | |
| P1433 | published in | Molecular and Cellular Biochemistry | Q1573176 |
| P1476 | title | Macrophage inflammatory protein-1alpha (MIP-1alpha) enhances a receptor activator of nuclear factor kappaB ligand (RANKL) expression in mouse bone marrow stromal cells and osteoblasts through MAPK and PI3K/Akt pathways | |
| P478 | volume | 304 |
| Q38218256 | AKT as a therapeutic target in multiple myeloma |
| Q43378586 | Animal Models of Cancer-Associated Hypercalcemia |
| Q42027903 | Bisphosphonates and statins inhibit expression and secretion of MIP-1α via suppression of Ras/MEK/ERK/AML-1A and Ras/PI3K/Akt/AML-1A pathways |
| Q35603116 | Bone anabolic agents for the treatment of multiple myeloma |
| Q95840053 | CCL3-CCR5 axis contributes to progression of esophageal squamous cell carcinoma by promoting cell migration and invasion via Akt and ERK pathways |
| Q37879210 | CCR1 as a target for multiple myeloma |
| Q36177928 | CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease |
| Q90401357 | Chemokines in Physiological and Pathological Bone Remodeling |
| Q32874862 | DLK1 is a novel regulator of bone mass that mediates estrogen deficiency-induced bone loss in mice. |
| Q35857559 | Effects of parathyroid hormone-related protein and macrophage inflammatory protein-1α in Jurkat T-cells on tumor formation in vivo and expression of apoptosis regulatory genes in vitro |
| Q39192262 | Gene silencing of the BDNF/TrkB axis in multiple myeloma blocks bone destruction and tumor burden in vitro and in vivo |
| Q42330053 | Glucosamine and chondroitin for the treatment of osteoarthritis |
| Q44971021 | Hyperocclusion up-regulates CCL3 expression in CCL2- and CCR2-deficient mice |
| Q37310621 | Immunomodulatory and anti-inflammatory effects of chondroitin sulphate |
| Q42071261 | In vivo hypobaric hypoxia performed during the remodeling process accelerates bone healing in mice |
| Q34450321 | Inhibition of BDNF in multiple myeloma blocks osteoclastogenesis via down-regulated stroma-derived RANKL expression both in vitro and in vivo |
| Q42077222 | Inhibitory effects of ZSTK474, a novel phosphoinositide 3-kinase inhibitor, on osteoclasts and collagen-induced arthritis in mice |
| Q42068905 | Mangiferin suppresses CIA by suppressing the expression of TNF-α, IL-6, IL-1β, and RANKL through inhibiting the activation of NF-κB and ERK1/2. |
| Q37546949 | Mitogen-Activated Protein Kinase 2 Signaling Shapes Macrophage Plasticity in Aggregatibacter actinomycetemcomitans-Induced Bone Loss |
| Q35063276 | Mouse Rankl expression is regulated in T cells by c-Fos through a cluster of distal regulatory enhancers designated the T cell control region |
| Q57794000 | Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies |
| Q34720969 | Osteoblast inhibition by chemokine cytokine ligand3 in myeloma-induced bone disease |
| Q39811943 | Potential enhancement of osteoclastogenesis by severe acute respiratory syndrome coronavirus 3a/X1 protein |
| Q42007201 | Proteinase-activated receptor (PAR)-2 activation impacts bone resorptive properties of human osteoarthritic subchondral bone osteoblasts |
| Q57021446 | RANKL-induced c-Src activation contributes to conventional anti-cancer drug resistance and dasatinib overcomes this resistance in RANK-expressing multiple myeloma cells |
| Q54976586 | Tanshinone IIA attenuates osteoclastogenesis in ovariectomized mice by inactivating NF-kB and Akt signaling pathways. |
| Q27024561 | Targeting tumor-stromal interactions in bone metastasis |
| Q53397945 | The Biological Activities of Oleocanthal from a Molecular Perspective. |
| Q47618731 | The MIP-1α autocrine loop contributes to decreased sensitivity to anticancer drugs |
| Q33607950 | The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma. |
| Q39196233 | The inhibitory effect of roasted licorice extract on human metastatic breast cancer cell-induced bone destruction. |
| Q38724068 | The macrophage inflammatory proteins MIP1α (CCL3) and MIP2α (CXCL2) in implant-associated osteomyelitis: linking inflammation to bone degradation |
Search more.